HC Wainwright Has Bullish Forecast for AXSM FY2026 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – HC Wainwright upped their FY2026 earnings estimates for Axsome Therapeutics in a note issued to investors on Monday, November 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($2.71) per share for the year, up from their prior estimate of ($4.10). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.39) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2026 earnings at ($0.27) EPS, Q1 2027 earnings at ($0.16) EPS and Q2 2027 earnings at $0.60 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Monday, November 2nd. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.38. The company had revenue of $259.69 million during the quarter, compared to analyst estimates of $249.19 million. Axsome Therapeutics had a negative net margin of 18.18% and a negative return on equity of 198.73%. The firm’s revenue for the quarter was up 51.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.94) EPS.

A number of other equities analysts have also commented on the stock. Wells Fargo & Company reaffirmed an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday, November 3rd. Royal Bank Of Canada lowered their price target on Axsome Therapeutics from $295.00 to $273.00 and set an “outperform” rating for the company in a report on Tuesday, November 3rd. Needham & Company LLC increased their price objective on Axsome Therapeutics from $267.00 to $268.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Morgan Stanley raised their price objective on Axsome Therapeutics from $247.00 to $249.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 3rd. Finally, Zacks Research raised Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $267.58.

Axsome Therapeutics Price Performance

Shares of AXSM stock opened at $140.97 on Wednesday. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.42 and a quick ratio of 1.34. The company has a market capitalization of $7.42 billion, a P/E ratio of -46.07 and a beta of 0.86. The company’s 50-day simple moving average is $175.16 and its two-hundred day simple moving average is $197.37. Axsome Therapeutics has a one year low of $123.00 and a one year high of $260.19.

Hedge Funds Weigh In On Axsome Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Axsome Therapeutics during the second quarter valued at approximately $759,695,000. Hillsdale Investment Management Inc. bought a new position in Axsome Therapeutics in the first quarter worth approximately $9,019,000. OneDigital Investment Advisors LLC purchased a new stake in Axsome Therapeutics during the second quarter worth $1,906,000. Baird Financial Group Inc. purchased a new stake in Axsome Therapeutics during the second quarter worth $2,497,000. Finally, Lisanti Capital Growth LLC purchased a new stake in Axsome Therapeutics during the second quarter worth $5,097,000. 81.49% of the stock is currently owned by institutional investors.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark Jacobson sold 10,000 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the transaction, the chief operating officer directly owned 10,000 shares in the company, valued at $2,086,500. This represents a 50.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 20.60% of the stock is currently owned by insiders.

Axsome Therapeutics Company Profile

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system disorders. The company is headquartered in New York and is led by founder, chairman and chief executive officer Herriot Tabuteau. Its marketed products include Auvelity, an oral treatment for major depressive disorder in adults, and Sunosi, which is used to improve wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.